/PRNewswire/ Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class.
Equities research analysts expect Clarus Therapeutics Holdings Inc (NASDAQ:CRXT – Get Rating) to announce sales of $4.80 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Clarus Therapeutics’ earnings. The lowest sales estimate is $4.40 million and the highest is $5.20 million. The company is expected to issue its […]
/PRNewswire/ Under the terms of Agreement Lipocine to receive: Up to $21.0 million in licensing fees, including $11.0 million payable immediately and $10.0.
CRXT OQ - Clarus Therapeutics Holdings Inc Key Developments reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.